Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can breast cancer drugs speed up aging? new study investigates

NCT ID NCT05700006

First seen Mar 17, 2026 · Last updated Jun 24, 2026 · Updated 16 times

Summary

This observational study enrolled 94 women with breast cancer to see if it's possible to collect blood, stool, and survey data from older patients taking aromatase inhibitors (a type of hormone therapy). The main goal was to test the feasibility of gathering this information for future research on how these drugs might affect aging. Participants provided samples and answered questionnaires over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

aromatase inhibitor (anastrozole, exemestane, or letrozole)

What this could lead to

If successful, this study could help design larger trials that clarify how hormone therapy affects aging in older breast cancer survivors.

What could go wrong

This is a small pilot study focused on feasibility, not on proving any effects on aging. Results may not lead to changes in treatment.

Conditions

The condition(s) this trial relates to.

Arthralgia breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.